HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it has established an “at-the-market” (“ATM”) program through which it may offer and sell up to $25 million of common stock from time to time, at Bio-Path’s discretion, through Cantor Fitzgerald & Co., acting as sales agent. Sales of Bio-Path common stock under the ATM program may be made directly on or through the Nasdaq Capital Market, among other methods.
Help employers find you! Check out all the jobs and post your resume.
